Adcetris

Active Ingredient(s): Brentuximab Vedotin
FDA Approved: * August 19, 2011
Pharm Company: * SEATTLE GENETICS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Adcetris Overview

Brentuximab vedotin (INN, trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T cell non-Hodgkin lymphoma).[1] Contents 1 Approvals and indications 1.1 Approval In Australia 2 Design 3 Clinical trials 4 Serious adverse events 4.1 ...

Read more Adcetris Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brentuximab_vedotin

Recent Adcetris Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Adcetris: (1 result)

Sorted by National Drug Code

• 51144-050 Adcetris 50 mg/10.5ml Intravenous Injection, Powder, Lyophilized, for Solution by Seattle Genetics, Inc.

Other drugs which contain Brentuximab Vedotin or a similar ingredient: (1 result)

• BRENTUXIMAB VEDOTIN 1 discussion